New Drug Trends in Obesity and Metabolic Diseases: Bio Stocks Have Ample Room for Further Gains

The pharmaceutical and biotech sectors, which had been left out during the semiconductor-led market rally, are now showing strong performance. The healthcare index is significantly outperforming the semiconductor index, attracting a surge in foreign buying. Easing of U.S. tariff risks and news of global new drug and technology transfers are boosting domestic investor sentiment.

Securities firms predict that this trend will continue into the first half of next year. The global trends in treatments for obesity and metabolic diseases, as well as domestic companies' technology exports and new drug approvals, are having a positive impact, leading analysts to believe there is ample room for further gains. Experts advise, "Through the end of the year, it is effective to develop a bio investment strategy alongside semiconductors and high-dividend stocks, in line with the rotational market."

[Industry No. 1 HighStockLoan direct link: https://www.hisl.co.kr/5113]

Meanwhile, interest in stock loans continues to rise. Investors who do not want to miss out on rare investment opportunities are turning to stock loans, which allow them to utilize more funds for stock purchases.

Additionally, even if investors using margin or credit experience a sharp drop in stock prices and face a forced sale, one of the advantages of stock loans is that they can easily switch without providing additional collateral or selling stocks, and simply wait for a rebound.

◆ HighStockLoan offers additional investment funds and credit/margin refinancing at the industry's lowest annual interest rate in the 4% range!

HighStockLoan has launched a securities-linked credit product with the industry's lowest annual interest rate in the 4% range, allowing anyone to use stock loans without burden. It can be used for both stock purchases and refinancing of securities firm margin/credit, and up to four times the investor's own capital can be utilized regardless of credit rating.

In addition, for investors who have found it difficult to use stock loans due to DSR limits, a product is also available that can be used regardless of DSR. Investors using the alternative exchange (NXT) can also take advantage of these offerings.

Investors interested in HighStockLoan's various customized products can contact the customer service center (☎1566-5113) for convenient consultation with a specialist at any time, 24 hours a day, regardless of loan approval.

○ Launched product with the industry's lowest annual interest rate in the 4% range

○ Offering products regardless of DSR

○ No. 1 market share for 21 consecutive years, Korea First Brand Award for 16 consecutive years

○ Real-time repayment of securities firm margin/credit

○ Trading available on the alternative exchange (NXT)

○ Reliable consultation quality guarantee system

* HighStockLoan Consultation Center: 1566-5113

Direct link: https://www.hisl.co.kr/5113

Ildong Pharmaceutical, CMTX, SPG, Now Robotics, Daewon Electric Wire

※ This content is unrelated to the editorial direction of The Asia Business Daily, and all responsibility lies with the information provider.

This content was produced with the assistance of AI translation services.